Tech Company Financing Transactions

Blueprint Medicines Funding Round

On 1/7/2014, Blueprint Medicines announced $25 million in Series B funding from Nextech Invest, Casdin Capital and F-Prime Capital.

Transaction Overview

Announced On
1/7/2014
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors

Nextech Invest (Lead Investor) (Thilo Schroeder)

Casdin Capital

F-Prime Capital

Third Rock Ventures (Alexis Borisy)

Proceeds Purpose
Blueprint's lead programs include the first known selective inhibitors of the KIT D816V mutation, which is the genomic driver of the underserved systemic mastocystosis patient population, as well as a key genomically defined subset of patients with gastrointestinal stromal tumors (GIST). The Company's pipeline also includes the first known isoform-selective FGFR4 inhibitors for patients with hepatocellular carcinoma with FGF19 amplification, the first clear genomic driver in liver cancer, and other tumors. Blueprint expects to initiate clinical trials for these programs in 2015.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
45 Sidney St. 200
Cambridge, MA 02139
USA
Email Address
Overview
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Profile
Blueprint Medicines LinkedIn Company Profile
Social Media
Blueprint Medicines Company Twitter Account
Company News
Blueprint Medicines News
Facebook
Blueprint Medicines on Facebook
YouTube
Blueprint Medicines on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffery Albers
  Jeffery Albers LinkedIn Profile  Jeffery Albers Twitter Account  Jeffery Albers News  Jeffery Albers on Facebook
Chief Medical Officer
Anthony Boral
  Anthony Boral LinkedIn Profile  Anthony Boral Twitter Account  Anthony Boral News  Anthony Boral on Facebook
Chief Scientific Officer
Marion Dorsch
  Marion Dorsch LinkedIn Profile  Marion Dorsch Twitter Account  Marion Dorsch News  Marion Dorsch on Facebook
Executive Vice President
Christoph Lengauer
  Christoph Lengauer LinkedIn Profile  Christoph Lengauer Twitter Account  Christoph Lengauer News  Christoph Lengauer on Facebook
VP - Bus. Development
Kate Haviland
  Kate Haviland LinkedIn Profile  Kate Haviland Twitter Account  Kate Haviland News  Kate Haviland on Facebook
VP - Finance
Michael Landsittel
  Michael Landsittel LinkedIn Profile  Michael Landsittel Twitter Account  Michael Landsittel News  Michael Landsittel on Facebook
VP - General Counsel
Tracey McCain
  Tracey McCain LinkedIn Profile  Tracey McCain Twitter Account  Tracey McCain News  Tracey McCain on Facebook
VP - Human Resources
Debbie Durso-Bumpus
  Debbie Durso-Bumpus LinkedIn Profile  Debbie Durso-Bumpus Twitter Account  Debbie Durso-Bumpus News  Debbie Durso-Bumpus on Facebook
VP - Operations
Christopher Murray
  Christopher Murray LinkedIn Profile  Christopher Murray Twitter Account  Christopher Murray News  Christopher Murray on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/7/2014: Onit venture capital transaction
Next: 1/7/2014: BioMedomics venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary